Resona Asset Management Co. Ltd. Has $53.85 Million Stock Position in Zoetis Inc. $ZTS

Resona Asset Management Co. Ltd. boosted its position in shares of Zoetis Inc. (NYSE:ZTS) by 1.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 427,933 shares of the company’s stock after purchasing an additional 7,464 shares during the period. Resona Asset Management Co. Ltd. owned 0.10% of Zoetis worth $53,851,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Global Wealth Strategies & Associates acquired a new stake in Zoetis during the fourth quarter valued at $25,000. Lodestone Wealth Management LLC acquired a new stake in Zoetis during the fourth quarter valued at $30,000. KERR FINANCIAL PLANNING Corp acquired a new stake in Zoetis during the third quarter valued at $31,000. Holos Integrated Wealth LLC acquired a new stake in Zoetis during the fourth quarter valued at $32,000. Finally, Elyxium Wealth LLC acquired a new stake in Zoetis during the fourth quarter valued at $32,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Performance

ZTS stock opened at $77.78 on Tuesday. The business’s fifty day moving average is $111.39 and its 200-day moving average is $120.28. The company has a quick ratio of 1.91, a current ratio of 3.15 and a debt-to-equity ratio of 2.80. The company has a market cap of $32.61 billion, a P/E ratio of 12.90, a price-to-earnings-growth ratio of 1.21 and a beta of 0.87. Zoetis Inc. has a twelve month low of $72.38 and a twelve month high of $172.23.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.60 by ($0.07). The company had revenue of $2.26 billion during the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. Zoetis’s revenue was up 2.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Equities research analysts forecast that Zoetis Inc. will post 6.91 EPS for the current year.

Insider Activity at Zoetis

In other Zoetis news, Director Michael B. Mccallister purchased 3,000 shares of the business’s stock in a transaction dated Monday, May 11th. The shares were bought at an average price of $77.76 per share, for a total transaction of $233,280.00. Following the completion of the acquisition, the director owned 24,524 shares in the company, valued at approximately $1,906,986.24. This trade represents a 13.94% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Paul Bisaro bought 2,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 13th. The stock was purchased at an average price of $75.88 per share, for a total transaction of $151,760.00. Following the acquisition, the director owned 27,862 shares of the company’s stock, valued at $2,114,168.56. This trade represents a 7.73% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have bought 11,650 shares of company stock valued at $886,384 over the last three months. 0.22% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. Morgan Stanley reissued an “overweight” rating and set a $115.00 price objective on shares of Zoetis in a research report on Friday. Stifel Nicolaus set a $105.00 price objective on Zoetis in a research report on Friday, May 8th. Citigroup reduced their price target on Zoetis from $145.00 to $112.00 and set a “buy” rating for the company in a research report on Monday. JPMorgan Chase & Co. reduced their price target on Zoetis from $190.00 to $130.00 and set an “overweight” rating for the company in a research report on Friday, May 8th. Finally, Bank of America boosted their price target on Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a research report on Friday, February 13th. Seven research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Zoetis has an average rating of “Hold” and a consensus price target of $134.75.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.